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Camargo de Andrade, Maria Claudina, Giovana Seno Di Marco,
Vicente de Paulo Castro Teixeira, Renato Arruda Mortara, Regiane
Ange´lica Sabatini, Joa˜o Bosco Pesquero, Miriam Aparecida Boim,
Adriana Karaoglanovic Carmona, Nestor Schor, and Dulce Elena
Casarini. Expression and localization of N-domain ANG I-converting
enzymes in mesangial cells in culture from spontaneously hypertensive
rats. Am J Physiol Renal Physiol 290: F364–F375, 2006. First published
August 16, 2005; doi:10.1152/ajprenal.00110.2005.— The angiotensin-
converting enzyme (ACE) profile in urine of hypertensive patients and
spontaneously hypertensive rats (SHR; 90- and 65-kDa N-domain
ACEs) is different from that of healthy subjects and Wistar rats (190
and 65 kDa). In addition, four ACE isoforms were purified from
mesangial cells (MC) of Wistar rats in the intracellular compartment
(130 and 68 kDa) and as secreted forms (130 and 60 kDa). We
decided to characterize ACE forms from SHR MC in culture. Analysis
of the ACE gene showed that SHR MC are able to express ACE
mRNA. The concentrated medium and cell homogenate were sepa-
rately purified by gel filtration and then subjected to lisinopril-
Sepharose chromatography. The molecular masses of purified en-
zymes, 90 kDa for ACEm1A and 65 kDa for ACEm2A (secreted
enzymes) and 90 kDa for ACEInth1A and 65 kDa for ACEInth2A
(intracellular), were different from those of Wistar MC. The purified
enzymes are Cl dependent, inhibited by enalaprilat and captopril,
and able to hydrolyze AcSDKP. Immunofluorescence and cell frac-
tionation followed by Western blotting showed predominant immu-
noreaction of the 9B9 antiserum for N-domain ACE in the nuclei. The
N-domain ACE was localized in the glomerulus from Wistar rats and
SHR. ANG II and ANG-(1–7) were localized in the cell cytoplasm
and nuclei. The 90-kDa N-domain ACE, described recently as a
possible genetic marker of hypertension, was found inside the cell
nuclei of SHR MC colocalized with ANG II and ANG-(1–7). The
presence of ANG II in the cell nuclei could suggest an important role
for this peptide in the transcription of new genes.
nuclei; hypertension; mesangial cell; regulation of gene expression
ANGIOTENSIN I-converting enzyme (ACE, peptidyl dipeptidase
A, kininase II, EC 3.4.15.1), a zinc-metallopeptidase, is in-
volved in the hydrolysis of ANG I, generating ANG II and
bradykinin (BK) and playing a critical role in blood pressure
regulation (43, 51). ACE can also cleave such peptides as
ANG-(1–7) (12), substance P (44), and AcSDKP (40), which
have been described as specific for N-domain ACE.
ACE has been purified and characterized from many differ-
ent tissues and species. ACE is a membrane-bound ectoenzyme
on the surface of endothelial, epithelial, and neuroepithelial
cells. Somatic ACE, which contains two homologous domains,
is a 140- to 190-kDa glycoprotein that displays a wide tissue
distribution. Male germinal cells in testicles (17, 21) also
synthesize a shorter 100- to 110-kDa form of ACE, identical to
the C-domain. ACE is also found in soluble form in lymph,
blood plasma, amniotic fluid, seminal plasma, and urine (7, 8,
20, 23, 29, 32, 33).
N-domain ACE has been described in body fluids. Deddish
et al. (13) found a naturally occurring short form of ACE with
only the N-domain active site in ileal fluid collected after
surgery. Casarini et al. (7) described 190- and 65-kDa ACE
isoforms in human urine from healthy subjects. They also
analyzed the urine from mildly hypertensive untreated patients
and separated 90- and 65-kDa isoforms of the N-domain ACE
(8). Furthermore, they studied ACE gene expression in Wistar
mesangial cells (MC) (6) and demonstrated for the first time
that these cells synthesize ACE mRNA. Andrade et al. (2)
purified and characterized four ACEs from Wistar rat MC: two
in the intracellular compartment, 130-kDa ACEInt1A (full-
length somatic ACE) and 68-kDa ACEInt2A (N-domain
ACE), and two as secreted forms, 130-kDa ACE1A and 60-
kDa ACE2A. On the basis of results from our laboratory
showing an ACE profile in hypertensive patients and sponta-
neously hypertensive rats (SHR) (90 and 65 kDa) that is
different from the ACE profile in healthy subjects and Wistar
rats (190 and 65 kDa), i.e., 90-kDa ACE, a possible genetic
marker of hypertension (35), we decided to investigate ACE
mRNA, protein expression, and the biochemical properties of
the secreted and intracellular ACE forms from cultured SHR
MC for comparison with the ACE isoforms from Wistar rat
MC. These results demonstrate the effective establishment of a
model of MC culture convenient for the study of renal synthe-
sis and release of N-domain ACE. In addition, we colocalized
the N-domain ACE with ANG II and ANG-(1–7) in the MC
nuclei.
MATERIALS AND METHODS
MC Culture
MC were cultured as described previously (27). Basically, macro-
dissected cortex was subjected to serial sieving, and MC were ob-
tained from collagenase treatment of isolated glomeruli to remove the
epithelial cell component. The cells were plated on RPMI 1640
supplemented with 20% FBS, 50 U/ml penicillin, 2.6 mM HEPES,
and 2 mM glutamine. The cultures were allowed to develop in a CO2
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incubator (5% CO2-95% air) at 37°C. Before the experiments, the
cells were incubated without FBS for 24 h. The medium and scraped
cells were stored at 80°C. Cells from passages 3–4 were charac-
terized according to the following criteria: 1) morphological aspect of
stellate cells, 2) positive immunofluorescence stain of cellular fi-
bronectin (clone FN-3E2, Sigma) and Thy 1.1 (Sigma), and 3)
negative stain of cytokeratin (clone C-11, Sigma) and human von
Willebrand factor.
Real-Time PCR for ACE Gene Expression
Total RNA was extracted from MC pellets using TRIzol reagent
according to the manufacturer’s protocol, and its purity was evaluated
by electrophoresis in 1% agarose gel. Contaminant genomic DNA in
RNA samples was avoided by treatment for 1 h at 37°C with DNase
I (1 U/2 g RNA). To the same quantity of RNA, 20 U of RNase-
OUT-RNase inhibitor and 3 mM MgCl2 were added. After the
incubation period, the samples were heated to 95°C and immediately
chilled on ice for DNase I denaturation. Reverse transcription was
performed using 2 g of total pure RNA, 200 U of Maloney murine
leukemia virus reverse transcriptase, 5 mM DTT, 50 ng of random
hexamer primers, 1 PCR buffer, 0.5 mM dNTPs, and 3 mM MgCl2.
Reactions were subjected to the following protocol: 20°C for 10 min,
42°C for 45 min, 95°C for 50 min, and 4°C for 10 min. Resultant
cDNA was then used for PCR as follows. Specific primers against rat
ACE were synthesized: 5-CTG CTA AGC AAC ATG AGC AG-3
(forward) and 5-GAT CCC CTG ATA CTT GGT TC-3 (reverse)
(Invitrogen, Carlsbad, CA). RT-PCR was carried out using a thermo-
cycler (model 7700, Applied Biosystems, Foster City, CA). Cycling
parameters were as follows: 4 min at 94°C and 27 cycles (50 s at
94°C, 50 s at 60°C, 1 min 20 s at 72°C, and 7 min at 72°C). The
expected 1,060-bp products (according to various known ACE se-
quences) were resolved on a 1% agarose gel stained with ethidium
bromide.
Purification of ACEs From Medium and Cells
Gel filtration on AcA-34. MEDIUM. The medium collected at pas-
sage 3 was concentrated in an Amicon concentrator. The concentrated
medium (2.0 ml) was subjected to gel filtration on an AcA-34 column
(1.5  100.8 cm, 178.0 ml) and equilibrated with 50 mM Tris HCl
buffer, pH 8.0, and 150 mM NaCl. Fractions (2.0 ml) were collected
at a flow rate of 20 ml/h. Protein concentration was monitored by
absorbance at 280 nm. Hippuryl-His-Leu (HHL) was used as substrate
to measure ACE activity.
MESANGIAL CELLS. After extraction of ACE from MC collected at
passage 3 in 4 ml of 50 mM Tris HCl buffer, pH 8.0, containing 1%
Triton X-114 and 500 M phenylmethylsulfonyl fluoride by shaking
for 1 h at 4°C, the sample was centrifuged at 3,000 rpm for 10 min at
4°C (14). The supernatant was concentrated in an Amicon concentra-
tor, and 2.0 ml were subjected to chromatography.
Affinity chromatography. The effluent from gel filtration of the
medium or MC on AcA-34 was applied separately to a lisinopril-
Sepharose column (50) equilibrated with 10 mM HEPES buffer, pH
8.0, containing 800 mM NaCl and 10 M ZnSO4. The ACEs were
eluted in 10 mM HEPES, pH 6.0, and 10 M ZnSO4. The optical
density of each fraction was quantified at 280 nm, and HHL was used
as substrate to determine ACE activity.
Enzymatic activity assay. ACE catalytic activity was measured
fluorometrically using 5 mM HHL (26) as substrate. The standard
buffer assay was 100 mM potassium phosphate, pH 8.3, containing
300 mM NaCl and 104 M ZnSO4. Aliquots of the enzymes were
incubated with 200 l of assay solution containing 5 mM HHL in the
standard buffer for 18 h at 37°C. The enzymatic reaction was halted
by the addition of 1.5 ml of 280 mM NaOH. At 10 min after addition
of 100 l of o-phthaldialdehyde (20 mg/ml) in methanol, the fluores-
cent reaction was stopped by the addition of 200 l of 3 N HCl. The
product, L-His-Leu, was measured fluorometrically (365 nm excita-
tion and 495 nm emission) using a fluorometer (model F-2000,
Hitachi).
Protein determination. Protein concentration was determined by
the Bradford method (4) (Bio-Rad Laboratories, Hercules, CA), ex-
cept when absorbance at 280 nm was used for the chromatographic
elution profile. Samples containing Triton X-114 were assayed with
the DC protein assay kit (Bio-Rad Laboratories).
Characterization of ACEs
Effect of Cl and temperature on ACE activity. The influence of
Cl concentration (50–1,500 mM) and temperature on ACE activity
was determined as described by Andrade et al. (2).
pH profiles of ACE. ACE activity at various pH values was
measured at 37°C by the fluorometric assay described above, with
HHL used as substrate, as described by Andrade et al. (2).
Fig. 1. RT-PCR of angiotensin-converting enzyme (ACE)
mRNA expression levels in mesangial cells (MC). Total RNA
was extracted from quiescent cultured MC from spontaneously
hypertensive rats (SHR) and Wistar rats. RT-PCR was per-
formed with specific primers, and products were resolved by
simple agarose gel electrophoresis. Plasmidial DNA was used
as positive control. ACE, angiotensin-converting enzyme; M,
molecular weight marker.
Table 1. Purification of ACE from medium of SHR MC culture
Volume,
ml
Protein
HHL,
mU/ml
Spec Act,
mU/mg
Purification,
times
Yield,
%mg/ml Total
Concentrated medium 2 1.2 2.4 1.14 0.95 1 100
Gel filtration AcA-34
ACEm1 11 0.048 0.528 0.054 1.12 1.17 22
ACEm2 19 0.038 0.722 0.090 2.36 2.48 30
Lisinopril-Sepharose
ACEm1A 3 0.007 0.021 0.036 5.14 5.41 0.875
ACEm2A 3 0.009 0.027 0.031 3.44 3.62 1.12
HHL, Hippuryl-His-Leu; Spec Act, specific activity; ACE, angiotensin-converting enzyme; SHR, spontaneously hypertensive rat; MC, mesangial cell.
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Km determination. Km was determined using HHL as substrate as
described by Andrade et al. (2). Lineweaver-Burk plots were used for
data analysis using Grafit version 3.0 (1992) (33).
Effect of inhibitors on ACE activity. Captopril, EDTA, and enala-
prilat were used as inhibitors as described previously by Andrade et
al. (2).
SDS-PAGE and Western blot analysis. SDS-PAGE and immuno-
blot analysis were carried out as previously described by Andrade et
al. (2). Purified protein (10 g) was subjected to 7.5% SDS-PAGE
and electrotransferred to a nitrocellulose membrane (Amersham Bio-
sciences). Antiserum 2E2 (Chemicon, Temecula, CA) was used at
1:1,000 dilution. Subsequent steps were carried out by the usual
development procedure with the streptavidin and phosphatase alkaline
system.
Hydrolysis of BK, ANG I, ANG-(1–7), and AcSDKP. An aliquot of
each ACE was incubated separately with BK, ANG I, ANG-(1–7),
and AcSDKP (Sigma) as described by Andrade et al. (2) and subjected
to HPLC as described by Casarini et al. (5).
Cell fractionation. Cells were harvested by scraping into 5 mM
HEPES, pH 7.4, containing 2 mM MgCl2 and 5 mM EDTA buffer
with protease inhibitors. Cells were incubated on ice for 10 min and
homogenized by five passages through a 22-gauge needle. The ho-
mogenate was centrifuged at 6,700 rpm for 7 min, and nuclei were
pelleted. The supernatant was centrifuged at 38,000 rpm for 1 h to
separate membrane (pellet) and cytosolic (supernatant) fractions. The
nuclear and membrane pellets were washed in 50 mM Tris, pH 8.0,
containing 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1%
SDS buffer and then centrifuged at 8,600 rpm for 30 min. Protein
extracts were analyzed by Western blot as described above.
Immunofluorescence. MC were grown directly on sterilized cover-
slips, fixed by incubation in 2% paraformaldehyde (in PBS) and 4%
sucrose for 10 min, and permeabilized in PBS with 0.1% Triton X-100
for 10 min. Fixed cells were incubated for 30 min with blocking buffer
(2% fetal calf serum, 2% albumin, and 0.2% fish gelatin in PBS) and
then with monoclonal antibody 9B9 (Chemicon) for the N-domain
portion of ACE (1:25 dilution) and anti-ANG-(1–7) (1:50 dilution)
and ANG II (1:50 dilution) polyclonal antibodies (gifts from Dr.
Preenie Senanayake, Cole Eye Institute, Cleveland, OH). The subse-
quent steps were carried out with tetramethylrhodamine isothiocya-
nate anti-rabbit IgG, FITC anti-mouse IgG, and 4,6-diamidino-2-
phenylindole (DAPI; Sigma). Results were analyzed by confocal laser
microscopy (Bio-Rad).
Immnufluorescence in a whole kidney. Kidneys from Wistar rats
and SHR were embedded in optimum cutting temperature compound
(OCT, Tissue Tek, Elkhart, IN), and 4-m-thick cryostat sections
were prepared. The sections on slides were washed three times for 10
min each with PBS and permeabilized for 40 min in PBS with 0.25%
gelatin and 0.1% sodium azide. The slides were incubated with
monoclonal antibody 9B9 and the polyclonal antibodies ANG-(1–7),
ANG II, and anti-DNA for 18 h. The subsequent steps were carried
out with tetramethylrhodamine isothiocyanate anti-rabbit IgG, FITC
anti-mouse IgG, and DAPI. Results were analyzed by confocal laser
microscopy (Bio-Rad). We also analyzed LLC-PK1 and Madin-Darby
canine kidney cells (American Type Culture Collection, Rockville,
MD) simultaneously with SHR MC to demonstrate the presence
of ACE.
Immunohystochemistry. Paraffin sections of renal tissue from SHR
were used to detect ACE expression. After fixation in the 10%
solution of paraformaldehyde, the specimens were embedded in par-
affin, cut into 4-m-thick sections, and examined by light microscopy.
Paraffin sections were used for immunohistochemical assays. Sections
were deparaffinized, and endogenous peroxidase activity was
quenched for 30 min with 0.3% H2O2. The sections were then washed
in PBS. Sections were incubated with monoclonal antibody 9B9 for
18 h at 4°C in a humidified chamber; sections incubated with PBS
served as controls. After they were rinsed, the slides were incubated
in horseradish peroxidase-conjugated secondary antibody (1:50 dilu-
tion) in 1% BSA in PBS for 30 min at room temperature. Bound
antibodies were visualized by the immunoperoxidase complex method
(peroxidase substrate-chromagen solution, 600 g/ml).
Apoptosis in MC induced by staurosporine. MC were grown
directly on sterilized coverslips. The cells were treated by incubation
with 50 M staurosporine (Sigma) for 20 h. The MC incubated with
RPMI 1640 without FBS served as controls. Morphological analysis
was also performed by labeling the cells with DAPI. Results were
analyzed by immunofluorescence microscopy.
NH2-terminal sequence of purified ACEs. The NH2-terminal se-
quence of ACEs was deduced from amino acid sequencing using a
protein sequencer (model PPSQ-23, Shimatzu).
RESULTS
Expression of ACE mRNA From SHR MC
Using specific primers against ACE, we were able to detect
the expression of this gene in SHR MC by RT-PCR (Fig. 1).
Purification of ACEs From Medium and Lysate of MC
Gel filtration of medium and lysate of MC on an AcA-34
column. Soluble ACE released into the medium was concen-
trated and applied to an AcA-34 column as described in
MATERIALS AND METHODS. Two peaks with ACE activity were
eluted: 90-kDa ACEm1 and 65-kDa ACEm2. Specific activi-
ties of the pooled fractions of ACEm1 and ACEm2 were 1.12
and 2.36 mU/mg, respectively (Table 1).
The lysate of MC concentrated supernatant (2.0 ml), with
ACE activity of 4.47 mU/ml and specific activity of 1.69
Table 2. Purification of ACE from SHR MC
Volume,
ml
Protein
HHL,
mU/ml
Spec Act,
mU/mg
Purification,
times
Yield,
%mg/ml Total
Concentrated supernatant 2.0 2.77 5.55 4.47 1.69 1 100
Gel filtration AcA-34
ACEInth1 15 0.027 0.405 0.223 8.25 4.88 7.3
ACEInth2 24 0.029 0.696 0.100 3.44 2.03 12.5
Lisinopril-Sepharose
ACEInth1A 6.2 0.006 0.037 0.220 36.7 21.7 0.67
ACEInth2A 8.5 0.017 0.144 0.290 17.1 10.1 2.6
Table 3. Inhibition of ACE activity from SHR MC
ACEm1A ACEm2A ACEInth1A ACEInth2A
Captopril (1 M) 52 52 72 68.5
EDTA (2.5 M) 65 81 45 57
Enalaprilat (2.5 M) 60 72 92 98
Values are expressed as percent inhibition.
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mU/mg, was applied to an AcA-34 column. The enzymatic
activity was separated into two peaks: 90-kDa ACEInth1
(specific activity 8.25 mU/mg), which appeared near the void
volume, and 65-kDa ACEInth2 (specific activity 3.44 mU/mg;
Table 2).
Affinity chromatography column. The fractions correspond-
ing to the peaks ACEm1 (0.054 mU/ml) and ACEm2 (0.090
mU/ml) from gel filtration of the medium were pooled sepa-
rately, and each pool was applied to a lisinopril-Sepharose
column. Only one peak with ACE activity was detected for
ACEm1, and pooled fractions (ACEm1A) presented a specific
activity of 5.14 mU/mg. For ACEm2, one peak with ACE
activity was also obtained, ACEm2A (specific activity 3.44
mU/mg; Table 1). Purified pooled samples from the cell lysate,
ACEInth1 (0.223 mU/ml) and ACEInth2 (0.100 mU/ml), from
the first step were applied separately to a lisinopril-Sepharose
column. One peak with ACE activity was detected for
ACEInth1, and the pooled fractions (ACEInth1A) presented a
specific activity of 36.7 mU/mg. When ACEInth2 was applied
to the same column, one peak with ACE activity (ACEInth2A)
was detected. The pooled fractions presented specific activity
of 17.1 mU/mg (Table 2).
The purified enzymes from Wistar rat MC were prepared as
previously described by Andrade et al. (2).
Characterization of ACE Activities
Effects of Cl and temperature on ACE activities. The NaCl
concentration required for maximal activation was 500 mM for
all purified ACEs (data not shown). The enzymatic activity of
purified ACEs was maintained at 4–37°C (data not shown).
Optimum pH. The optimum pH determined for ACEm1A
and ACEm2A was 8.0, and that for ACEInth1A and
ACEInth2A was 7.5 (data not shown).
Fig. 2. SDS-PAGE (7.5%) analysis of re-
duced purified ACEs from SHR (A and B)
and Wistar rat (C and D) MC. Aa: standard
protein (lane 1) and 10 g of ACEm1A
(lane 2). Ab: 10 g of ACEm2A (lane 1)
and standard protein (lane 2). Ba: 10 g of
ACEInth1A (lane 1) and standard protein
(lane 2). Bb: 10 g of ACEInth2A (lane 1)
and standard protein (lane 2). Ca: 10 g of
ACE1Aw (lane 1) and standard protein
(lane 2). Cb: 10 g of ACE2Aw (lane 1)
and standard protein (lane 2). Da: 10 g of
ACEInt1Aw (lane 1) and standard protein
(lane 2). Db: 10 g of ACEInt2Aw (lane 1)
and standard protein (lane 2). Protein was
stained with Bio-Rad silver.
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Km values, with HHL used as substrate. Km values deter-
mined for HHL hydrolysis were 2 mM for ACEm1A and
ACEm2A from medium culture and 3 mM for ACEInth1A and
ACEInth2A from MC.
Inhibition of ACE activity. The effects of captopril, enala-
prilat, and EDTA inhibitors of ACE on HHL hydrolysis are
presented in Table 3.
SDS-PAGE. The molecular mass of ACEm1A and
ACEInth1A was 90 kDa and that of ACEm2A and ACEInth2A
was 65 kDa. Figure 2 shows the molecular mass of purified
ACE forms from medium (130 and 60 kDa) and intracellular
compartment (130 and 68 kDa) of Wistar rat MC. All puri-
fied ACEs analyzed under dissociating conditions were
homogeneous.
Western blot analysis. ACE isoforms were studied by West-
ern blot analysis using the 2E2 antibody (Fig. 3). The enzymes
purified from Wistar rat MC were also recognized by the same
specific antibody for ACE (data not shown).
Hydrolysis of BK, ANG I, and ANG-(1–7) and products
of AcSDKP hydrolysis. The enzymatic activities of purified
ACEs were analyzed using the best-known physiological sub-
strates ANG I and BK. All enzymes were capable of convert-
ing ANG I to ANG II and hydrolyzing BK at the Pro7-Phe8
peptide bond, liberating Arg1-Pro7 (Table 4). The results of
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Western blot analysis of purified ACEs from SHR MC using 2E2 antibody and cell fractionation of SHR MC. Aa: ACEm1A (lane 1) and standard protein
(lane 2). Ab: ACEm2A (lane 1) and standard protein (lane 2). Ba: ACEInth1A (lane 1). Bb: standard protein (lane 2) and ACEInth2A (lane 3). C: cell
fractionation of SHR MC. MC fractions were analyzed by Western blot using monoclonal antibody 9B9. Lane 1, membrane; lane 2, cytosol; lane 3, nuclei; lane
4, standard protein.
Table 4. Substrate hydrolysis by ACEs from SHR and Wistar rat MC
Peptides
SHR Wistar Rats
ACEm1A ACEm2A ACEInth1A ACEInth2A ACE1A ACE2A ACEInt1A ACEInt2A
BK 51 50 51 50 50 50 50 50
ANG I 43 45 43 45 40 45 30 50
ANG (1–7) 50 63 50 63 10 68.5 12 67.7
AcSDKP 49 47 49 47 15 45 10 50
Enzymes were incubated with 5 g/ml substrate for 3 h at 37°C. Values are expressed as percent hydrolysis in relation to 0 min of reaction (n  2). Percent
hydrolysis was calculated as IC50. BK, bradykinin.
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hydrolysis of ANG-(1–7) and AcSDKP, described as specific
substrates for N-domain ACE by ACEm1A, ACEm2A,
ACEInth1A, and ACEInth2A, are shown in Table 4.
Cell fractionation. Western blot analysis of nuclei, cyto-
plasm, and membrane isolated by cell fractionation using
monoclonal antibody 9B9 against N-domain ACE showed
predominant immunoreaction in the nuclei (Fig. 3).
Cell surface colocalization of ACE with ANG II and ANG-
(1–7). To confirm the cell surface localization of N-domain
ACEs from SHR MC, these cells were grown to confluence
and probed with a monoclonal ACE antibody. Results of
confocal microscopy are shown in Figs. 4 and 5. The nucleus
from MC was localized with DAPI used as control. Wistar rat
MC were analyzed under the same conditions used for controls
(Figs. 6 and 7). SHR MC were incubated with staurosporine
and analyzed by fluorescence microscopy. Our results demon-
strate that the MC were not apoptotic. The same procedure was
used for Wistar rat MC (data not shown).
Immunohistochemistry. We analyzed the SHR kidney sec-
tion with antibodies against ACE, ANG II, and ANG-(1–7)
using immunoperoxidase-antiperoxidase complex and immu-
nofluorescence staining (Fig. 8). To demonstrate the presence
of N-domain ACE in the cell nuclei, we also compared SHR
MC with Madin-Darby canine kidney and LLC-PK1 cells, as
negative and positive controls, respectively (Fig. 9).
ACEInth1A and ACEInth2A NH2-Terminal Sequence
The NH2-terminal sequence of purified ACEInth1A and
ACEInth2A is shown in Fig. 10.
DISCUSSION
Andrade et al. (2) purified and characterized four enzymes
from Wistar rat MC in culture: 130-kDa ACEInt1A and 68-
kDa ACEInt2A from the intracellular compartment and 130-
kDa ACE1A and 60-kDa ACE2A as secreted isoforms. On the
basis of the results showing that SHR MC are able to express
ACE mRNA and that the ACE profile (90 and 65 kDa) of
hypertensive patients and SHR (8, 35) differs from that of
healthy subjects (190 and 65 kDa) (7), the 90-kDa ACE being
a possible genetic marker of hypertension, we decided to
analyze the biochemical and enzymatic properties of the se-
creted and intracellular ACE isoforms from SHR MC in culture
and compare them with those of MC enzymes from Wistar rats
and also to locate the isoforms in those cells.
With use of gel filtration chromatography on an AcA-34
column followed by a lisinopril-Sepharose column, ACEm1A
(5.4-fold) and ACEm2A (3.6-fold) were purified from the
medium and ACEInth1A (21.7-fold) and ACEInth2A (10.1-
fold) from the cell lysate of SHR MC in culture.
Fig. 4. Colocalization of ACE and ANG-
(1–7) in SHR MC. A: 4,6-diamidino-2-phe-
nylindole (DAPI). B: localization of N-do-
main ACE using 9B9 monoclonal antibody.
C: localization of ANG-(1–7). D: B and C
superimposed to show colocalization of N-
domain ACE and ANG-(1–7). Original mag-
nification 40.
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Molecular masses of 90 kDa for ACEm1A and ACEInth1A
and 65 kDa for ACEm2A and ACEInt2A were similar to those
previously published for the ACEs from urine of mildly hy-
pertensive untreated patients (8) and SHR (35). Molecular
masses of ACEm2A and ACEInt2A were similar to those
described for the secreted and intracellular ACE isoforms
purified from Wistar rat MC (2). The molecular masses of
these enzymes were much lower than that of testicular ACE
(90–100 kDa), which is heavily glycosylated, but were similar
to those of the nonglycosylated form of the single-domain
testicular ACE (76–84 kDa) (25, 36) and the N-domain ACEs
(65–68 kDa) from human and rat urine (7, 8, 28, 35) and ileal
fluid (13). When electroblotted to a nitrocellulose membrane,
all enzymes purified from Wistar rat and SHR MC in culture
reacted strongly with 2E2 antibody against ACE.
With HHL used as substrate, the optimum pH for ACEm1A,
ACEm2A, ACEInth1A, and ACEInth2A was similar to that
described for the purified ACEs from Wistar rat MC (2).
Similar values were found in the literature for different ACEs:
pH 8.4 for ACE from the microvillous membrane of pig kidney
with HHL used as substrate (38), pH 7.5, 8.5, and 7.5 with
Z-Phe-His-Leu, Z-Pro-Phe-His-Leu, and ANG I, respectively,
used as substrates for ACE from human serum (41), and pH 8.0
with HHL used as substrate for urinary ACEs from normal
subjects and premature and full-term infants (28).
The purified ACE activities from SHR MC were maintained
at 4°C and 37°C but were decreased at high temperatures
(50°C and 95°C). This profile was the same as that obtained by
Andrade et al. (2). Similar results were described by Nishimura
et al. (37), who studied the effect of preincubation at 50°C on
the ACE activities isolated from human lung homogenate.
All enzymes from SHR MC showed Cl dependence. The
hydrolysis by ACEm1A, ACEm2A, ACEInth1A, and ACEInth2A
was catalyzed more rapidly at 500 mM, in contrast to the ACE
activities from Wistar rat MC (2), which showed maximal
activation at 300 mM. These results are distinct from the data
described for renal ACE, which showed maximal activation at
800 mM Cl (49), and also from ileal ACE, with maximal
activation at 10 mM Cl (13). The alternative anion activation
may have been introduced as a regulatory device; however, this
is unlikely for conversion of ANG I to ANG II by endothelial
ACE. Epithelial ACE at other locations (e.g., intestinal and
renal tubular brush borders) is exposed to large ion fluxes and
may be regulated in such a manner (18).
ACEs purified from SHR MC were inhibited by 1 M
captopril and enalaprilat, as were N- and C-domain recombi-
nant ACE, ileal fluid ACE, and MC ACE from Wistar rats (2,
13). This inhibition of N-domain ACE suggests that these
enzymes could have a special conformation with specific and
different bonds with these inhibitors. The COOH-terminal
sequence of the N-domain ACEs demonstrated that they are
truncated somewhere between S482 and P637 (data not
shown). This short amino acid sequence could be responsible
for the conformational changes.
Fig. 5. Colocalization of ACE and ANG II
in SHR MC. A: DAPI. B: localization of
N-domain ACE using 9B9 monoclonal anti-
body. C: localization of ANG II. D: B and C
superimposed to show colocalization of N-
domain ACE and ANG II. Original magni-
fication 40.
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The Km obtained for purified ACEs from Wistar rat (2) and
SHR MC was similar to that for ACEs from rabbit lung (30),
rat serum (41), human kidney (45), and human urine (7, 8, 28)
and wild-type recombinant ACE, with a Km of 103 M with
HHL used as substrate (49). ANG I and BK are among the
physiologically important substrates of ACE; conversion of
ANG I and inactivation of BK may be relevant in explaining
the changes in glomerular hemodynamics. Hydrolysis of the
physiological ACE substrates ANG I and BK by purified
ACEm1A, ACEm2A, ACEInth1A, and ACEInth2A was sim-
ilar to hydrolysis of ACEs from Wistar rat MC (2).
ANG-(1–7) is an active metabolite released by peptidases
from ANG I or ANG II. Enzymes necessary for the production
and inactivation of ANG-(1–7) are abundant in the kidney and
have been found in urine (10, 22). In contrast to ANG II, the
cumulative effects of ANG-(1–7) suggest an antihypertensive
role for the heptapeptide. ANG-(1–7) exhibits vasodepressor
effects on the coronary and mesenteric vascular beds (16). The
evidence that ANG-(1–7) can affect the function of the whole
kidney was based on the observation that the heptapeptide had
a positive effect on glomerular filtration rate in the absence of
a change in renal vascular resistance and also increased water
and electrolyte excretion (10). The pharmacological effects of
this peptide may be attributed to indirect potentiation of the
action of BK on its B2 receptor by binding to the active site of
ACE (12). Deddish et al. (12) reported 100-times-faster cleav-
age of ANG-(1–7) to ANG-(1–5) and His-Pro by N-domain
ACE than by C-domain ACE, showing that ANG-(1–7) is a
relatively specific substrate of N-domain ACE. Our results
demonstrate that ACEs purified from MC in culture from SHR
hydrolyzed this substrate better than ACE1A and ACEInt1A
from Wistar rat MC (2).
The tetrapeptide AcSDKP, also highly specific for N-do-
main ACE (40), was hydrolyzed better by ACEs purified from
SHR MC and by ACE2A and ACEInt2A from MC of Wistar
rats. This result was similar to that reported by Hattori et al.
(28) and Casarini et al. (8). The hydrolysis of ANG-(1–7) and
AcSDKP, specific substrates of the N-domain site, by the
enzymes purified from SHR MC suggested that they are
N-domain ACEs.
The NH2-terminal sequencing studies showed that ACEInth1A
and ACEInth2A were similar in somatic rat, mouse, and human
ACEs, proving that these enzymes contain the NH2-terminal
portion of the molecule (45).
Immunofluorescence by confocal microscopy showed that
N-domain ACE was expressed inside the nuclei of SHR MC,
but not on the cell surface, and also that N-domain ACE was
colocalized with ANG II and ANG-(1–7), the product and
substrate for N-domain ACE. We also localized N-domain
ACE inside the nuclei of Wistar rat MC and somatic ACE in
the membrane, which distinguishes this profile from that of
SHR MC. Danilov et al. (11) reported that the monoclonal
Fig. 6. Colocalization of ACE and ANG-
(1–7) in Wistar rat MC. A: DAPI. B: local-
ization of N-domain ACE using 9B9 mono-
clonal antibody. C: localization of ANG-(1–
7). D: B and C superimposed to show
colocalization of N-domain ACE and ANG-
(1–7). Original magnification 40.
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antibody against ACE recognized at least nine different
epitopes located in the N-domain and that monoclonal antibod-
ies were not able to bind well to the C-domain portion of the
ACE. After incubation of MC with staurosporine, we demon-
strated that MC were not apoptotic and that there was no
leakage of cytosolic protein into the nucleus. Comprehension
of the physiological roles of these natural N-domain ACEs
in the cell nuclei requires studies using potential specific
inhibitors.
N-domain ACE was detected in glomerulus from Wistar rats
and SHR by immunofluorescence of a whole kidney section. In
the same sections from SHR, ANG-(1–7) was localized in
tubule and glomerulus, but ANG II was found predominantly
only in glomerulus from SHR. These results showed that both
peptides and N-domain ACE were present in MC from whole
kidney, supporting the theory that, in vivo, MC express the
N-domain ACE. Recently, using immunostaining, Ferrario et
al. (24) showed ANG-(1–7) in the kidney of five SHR (3
treated with vehicle and 2 exposed to omapatrilat). Intense
ANG-(1–7) staining, more pronounced in omapatrilat-treated
SHR, was found in renal proximal tubules throughout the outer
and inner regions of the renal cortex and the thick ascending
loop of Henle, whereas no ANG-(1–7)-positive immunostain-
ing was found in glomerulus or distal tubules. These data
differed from our results, which showed ANG-(1–7) in MC
from SHR and Wistar rats. The presence of MC in the glomer-
ulus supporting glomerular capillaries differs from the report
by Ferrario et al. Immunofluorescence data demonstrated
ANG-(1–7) production in glomerulus and MC, suggesting that
this peptide may contribute to the regulation of renal function
and blood pressure.
The results described here and in previous studies demon-
strate that all components of the renin-angiotensin system are
present in MC and that ANG II is produced by the same cells,
predominantly in the nucleus, suggesting an intracrine action
of renin, ACE, ANG II, and ANG-(1–7). This production
occurs in the cells that have been serum deprived for 24 h,
indicating the natural production of peptides (1, 2, 34, 48). As
described by Chai and Danser (9), ANG synthesis at tissue
sites is well established and depends largely, if not completely,
on kidney-derived renin. There is still debate over the exact
tissue site of ANG generation (extracellular fluid, cell surface,
or intracellular compartment). Recently, it was reported that
the actions of intracellular ANG II might be mediated by direct
nuclear effects and/or interaction with nuclear AT1-like recep-
tors (3, 25). ANG II accumulation inside the nucleus has been
found in other tissues, including myocardium, brain, smooth
muscle, and adrenal glands (3, 15, 19, 39). Van Kats et al. (47)
demonstrated that local ANG II synthesis in adrenal and kidney
occurs predominantly extracellularly and is followed by rapid
receptor-mediated endocytosis, leading to high intracellular
levels. Navar et al. (36) described elevations in intrarenal ANG
Fig. 7. Colocalization of ACE and ANG II
in Wistar rat MC. A: DAPI. B: localization of
N-domain ACE using 9B9 monoclonal anti-
body. C: localization of ANG II. D: B and C
superimposed to show colocalization of N-
domain ACE and ANG II. Original magni-
fication 40.
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II by several processes, leading to levels much greater than can
be explained from the circulating levels. In ANG II-dependent
hypertension, ANG II is internalized via an AT1 receptor
mechanism, but intrarenal production of ANG II is also sus-
tained. Using radioligand binding on wild-type mouse kidneys,
Santos et al. (42) demonstrated cell-specific binding of ANG-
(1–7), and they suggested that the physiological effects of this
peptide occur through an interaction with its own receptor.
Cell fractionation for the isolation of nuclei, cytoplasm, and
membrane followed by Western blot analysis of each fraction
showed the predominant immunoreaction in the nuclei of MC
from Wistar and SHR when 9B9 antiserum against ACE was
used, confirming the data obtained by confocal microscopy.
Therefore, we have described for the first time the localiza-
tion of N-domain ACE inside the cell nuclei. Iborra et al. (29)
detected nuclear sites of protein translation by labeling perme-
 
 
 
 
 
 
Fig. 8. N-domain ACE, ANG II, and ANG-(1–7) detection by immunohystochemistry. A and B: immunoperoxidase-antiperoxidase complex immunostaining.
A: negative control. B: N-domain ACE detection using 9B9 monoclonal antibody. Original magnification 400. Arrows, ACE localization. C–E: immunoflu-
orescence detection. C: N-domain ACE detection using 9B9 monoclonal antibody analyzed by confocal laser microscopy. D: ANG II detection in glomeruli (G)
and proximal tubule (PT) using polyclonal antibody. E: ANG-(1–7) detection in glomeruli and proximal tubule using polyclonal antibody. Original magnification
40.
Fig. 9. Immunodetection of N-domain ACE using 9B9 monoclonal antibody. A: Madin-Darby canine kidney cells (negative control). B: LLC-PK1, a cell line
derived from Hamphsire pigs with many morphological and physiological similarities to mammalian proximal tubule (positive control). C: SHR MC.
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abilized mammalian cells or purified nuclei with fluorescent
lysine and also detected discrete sites of transcription and
translation within the nuclei. In their study, the accumulation of
nuclear fluorescence was time dependent and sensitive to
inhibitors of protein synthesis (cycloheximide and puromycin).
The authors estimated that the nuclear fluorescence represents
protein synthesis in the nucleus. However, evidence reported
by Iborra et al. showed that it is necessary to verify whether
these particles represent cytoplasmic contamination or are
synthesized in the nuclei.
Although our results suggest for the first time the presence of
N-domain ACE inside the cell nuclei of SHR and Wistar rat
MC and colocalization of ACE with ANG II and ANG-(1–7),
we need to elucidate the shedding, degradation, and cellular
traffic of these N-domain ACE isoforms and clarify whether
these enzymes originate from an alternative splicing of the
ACE mRNA or from posttranslational modification.
The presence of ANG II in the cell nuclei could suggest an
important role for this peptide in the regulation of gene ex-
pression, as described by Erdmann et al. (19) when they
localized ANG II to the nuclei in cerebellar neurons and to the
transcriptionally active euchromatin in endothelial and granule
cells.
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